Immunosuppressive T-cell antibody induction for heart transplant recipients
Key result
Interleukin-2 receptor antagonist induction reduced acute rejection compared with no induction (33% vs 45%, RR 0.73) in a fixed-effect model, though random errors cannot be excluded.
Why the study?
Does immunosuppressive T-cell antibody induction reduce acute rejection or mortality in heart transplant recipients?
Population
1427 heart-transplant recipients pooled from 22 randomized clinical trials
Comparison
Immunosuppressive T-cell antibody induction vs Placebo, no antibody induction, or another kind…
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Implication
IL-2RA induction may reduce acute rejection post-heart transplant; larger RCTs needed to confirm benefit and assess mortality.
Study Design
Type
Systematic Review (n=1,427)
Structured PICO
Does immunosuppressive T-cell antibody induction reduce acute rejection or mortality in heart transplant recipients?
P
Population
1,427 heart transplant recipients from 22 randomized clinical trials evaluating the benefits and harms of immunosuppressive T-cell antibody induction therapies.
I
Intervention
Immunosuppressive T-cell antibody induction (including interleukin-2 receptor antagonists [IL-2 RA], monoclonal antibodies, or polyclonal antibodies)
C
Comparator
Placebo, no antibody induction, or another kind of antibody induction (all participants received the same maintenance immunosuppressive therapy within individual trials)
O
Outcome
Mortality, acute rejection, infection, Cytomegalovirus (CMV) infection, post-transplantation lymphoproliferative disorder, cancer, adverse events, chronic allograft vasculopathy, renal function, hypertension, diabetes mellitus, and hyperlipidaemiahard clinical
Main Result
Relative Risk: 0.73 (95% CI 0.59–0.9)
Absolute Event Rate: 33% vs 45%
Current evidence is insufficient to demonstrate clear benefits or harms of T-cell antibody induction in heart transplant recipients, highlighting the need for larger, high-quality randomized trials.
Limitations
- All included trials were at high risk of bias
- Trial sequential analysis indicated required information sizes were not reached
- Significance of findings depended on the statistical model used (fixed vs random effects)
- Definitions of adverse events varied between trials
- Numbers of participants and events were too small to allow definitive conclusions
- Small number of trials
- Limited number of participants and outcomes
- High risk of bias in included trials
- Varying definitions of adverse events between trials
- Trial sequential analyses could not exclude random errors
Cite This Study
Penninga et al. (2013) conducted a systematic review in Heart transplant (n=1,427). Interleukin-2 receptor antagonist (IL-2 RA) induction vs. No induction was evaluated on Acute rejection (RR 0.73, 95% CI 0.59 to 0.90). Interleukin-2 receptor antagonist induction reduced acute rejection compared with no induction (33% vs 45%, RR 0.73) in a fixed-effect model, though random errors cannot be excluded.